Biosimilars, high-yielding CHO cell lines, scalable processes
We offer both ready-to-use and on-request biosimilar cell lines and production processes, with flexible deal terms.
With over 20 years of experience, we utilize state-of-the-art technology and employ top-notch experts in process science, manufacturing, analytics, and quality to develop robust and high-yielding cell lines in record time.
With over 20 years of experience, we utilize state-of-the-art technology and employ top-notch experts in process science, manufacturing, analytics, and quality to develop robust and high-yielding cell lines in record time.
What we offer
- Over a dozen ready-to-use cell lines that produce biosimilars, including pembrolizumab, trastuzumab, rituximab, adalimumab, and more
- With many more biosimilars in development including monoclonal antibodies, fertility-related hormones (FSH, HCG), growth hormones, and EPOs
- Suspension-based, stable, monoclonal, CHO cell lines
- GMP-compliant, master cell banks available
- All supporting documentation for regulatory submissions
- Scaleable GMP-ready Upstream and Downstream processes
- Chemically defined media and feeds, both proprietary and commercial